CHN Analyser for Contract Research Organisati?ons and Service Labs
The Model 440 CHN analyser from Exeter Analytical Inc. has become the system of choice for many Contract research organisations and service labs because of its proven ability to accurately analyse the widest range of sample types, quickly, easily and reliably.
Operating across a wide linear range, the Model 440 is capable of routinely determining percentage carbon, hydrogen and nitrogen levels in almost any sample type including organic compounds, pharmaceuticals, petrochemicals, polymers, refractory, environmental or natural materials (soil, plants or insects).
The Model 440 delivers unmatched productivity and top quality results as it benefits from a furnace design that prevents cross contamination and allows the running of a greater number of samples between combustion tube changes.
Based upon a unique combined static/dynamic combustion technology, the Model 440 can precisely analyse the widest range of sample types from volatile to difficult to combust materials including nitrides, graphite fibres, ceramics and even carbides with melting points in excess of 2000 °C.
Offering unmatched operating accuracy and precision, the fully automated Model 440 delivers simultaneous CHN analysis in less than 5 minutes.
Low gas and reagent consumption combined with high reduction tube life allows the Model 440 to deliver some of the lowest operating costs of any CHN elemental analyser available. Intuitive Windows based operating software reduces human errors through incorporation of extensive automation, comprehensive customer help and diagnostic facilities. Most parts on the Model 440 are user replaceable further reducing operating costs and downtime.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance